Yung-jue J. Bang
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 220 publications
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 19, 2025
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 04, 2024
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.
Journal: Future oncology (London, England)
Published: June 11, 2024
Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 31, 2024
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.
Journal: Journal for immunotherapy of cancer
Published: January 27, 2024
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
Journal: Nature medicine
Published: November 09, 2023
A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer.
Journal: Cancer research and treatment
Published: October 10, 2023
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies.
Journal: Japanese journal of clinical oncology
Published: September 18, 2023
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Journal: The Lancet. Oncology
Published: September 07, 2023
Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.
Journal: Cancer research communications
Published: June 28, 2023
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Journal: Nature medicine
Published: May 05, 2023
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Journal: Lancet (London, England)
Published: February 28, 2023
Last Updated: 09/26/2026